Florent PRUDHOMME

[D-3 Flow Chemistry Webinar] 📅 Join us next Monday 𝐀𝐩𝐫𝐢𝐥 𝟐𝟐𝐧𝐝 𝐚𝐭 𝟓𝐏𝐌 𝐂𝐄𝐓 / 𝟏𝟏𝐀𝐌 𝐄𝐓 for our SEQENS Pharmaceutical Solutions 𝐰𝐞𝐛𝐢𝐧𝐚𝐫!   ⏳It is still time to register! Connect with jean-baptiste Rouchet, Ph.D. and Jean-Yves LENOIR and 𝐥𝐞𝐚𝐫𝐧 𝐡𝐨𝐰 𝐭𝐨 𝐢𝐦𝐩𝐫𝐨𝐯𝐞 𝐭𝐡𝐞 𝐬𝐚𝐟𝐞𝐭𝐲 𝐚𝐧𝐝 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞𝐧𝐞𝐬𝐬 𝐨𝐟 𝐲𝐨𝐮𝐫 𝐩𝐫𝐨𝐜𝐞𝐬𝐬 𝐮𝐬𝐢𝐧𝐠 𝐅𝐥𝐨𝐰 𝐂𝐡𝐞𝐦𝐢𝐬𝐭𝐫𝐲.   𝐃𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐢𝐬 𝐰𝐞𝐛𝐢𝐧𝐚𝐫 𝐲𝐨𝐮 𝐰𝐢𝐥𝐥 𝐥𝐞𝐚𝐫𝐧: ✔️How to assess whether a Flow chemistry process should be studied as an alternative for your API synthesis, ✔️Insights on ICH Q13 guidance and how reproducibility and quality can be improved using continuous processes, ✔️Strategies to optimize a continuous process for an easier upscaling   𝐓𝐨 𝐫𝐞𝐠𝐢𝐬𝐭𝐞𝐫 ➡ https://lnkd.in/e2sUgA2X

25

📢Meet Katrin Wuelfing, one of our Senior Scientist & our Transfer Project Leader ! 1) What do you do at AdhexPharma ? I am a Senior Scientist & Transfer Project Leader at AdhexPharma, which means that I am responsible for transferring products, that have already been commercialized on the market, to our production site in Chenôve at AdhexPharma. I am involved from the first enquiry from a new customer until the product is manufactured in Chenôve, which also involves regular contact with our customers, e.g. with regular meetings to ensure that the project is on track and the transfer is successful.    2) What is your favorite benefit of planar dosage forms ? One of my favorite benefits is that planar dosage forms offer a convenient alternative to other dosage forms such as injections or tablets. Patients can use films and patches themselves without the need for someone to assist them (e.g. with injections) and it is much easier to use, as it is difficult for people who have difficulty swallowing pills, for example. This gives each patient much more independence and freedom.   3) Can you tell us three things on your bucket list ? Crossing the alps on foot Exploring Canada by car, foot and train Start horseback riding again   #projectmanagement #management #pharma #expert #scientist #science #healthcare #innovation

30

Meet our new group leader Julien Duxin who moves to Biotech Research & Innovation Centre (BRIC), University of Copenhagen today. We are very happy to welcome you and your research group. 👋 Let us introduce you to the Duxin Lab and their use of Xenopus frog-egg 👇🐸   The Duxin-group investigates the process of genome duplication and maintenance with a particular focus on how lesions induced on DNA from chemo therapeutic agents are repaired. By using extracts from frog-eggs as model systems they have discovered how the protein RFWD3 is crucial for our DNA maintenance. 🧬️ The protein extracts from Xenopus frog-egg have the same DNA repair proteins as the human body. By adding a DNA substrate containing a defined DNA lesion to the extract, they can study how the lesion in question is repaired. “We combine biochemical work using those Xenopus eggs extracts with cellular work. And by doing that we can get a deep understanding of the repair mechanism which can be difficult to achieve in cells,” explains Julien Duxin. The cell-free environment enables the group to manipulate the system in a way that is not possible in the human body. Apart from Julien Duxin, the Duxin-group consists of 11 researchers from postgraduate level to PhD’s and postdocs, who will transfer their research from Center for Protein Research to BRIC due to the close of the center in 2026. Asked what characterizes the Duxin-group, Julien Duxin emphasizes their collaboration with other research groups and their ability to feed from and add to the environment they are part of. According to the group leader the move to BRIC will provide them new scientific opportunities and enables them to use methods they have never used before. “My lab is really a biochemical lab, and thanks to the CPR environment we are now doing cryo-EM structural studies in Xenopus egg extracts and CRISPR-Cas9 screens in human cells. We are looking forward to our move to BRIC to provide but also to pick up new expertises,” he says. That approach to collaboration moves with the Duxin-group, he says. “Our lab is in a transition, and I want to continue in that direction by bringing a multi-disciplinary approach or multi-expertise approach to get back to our central question: How does a repair mechanistically occur?”. Welcome, Duxin Group. https://lnkd.in/drweecs9

190

1 commentaire

Register for MBEC 2025 to see Dr. Luc Joyeux discuss his team's translational research journey from animal experiments to the implementation a phase-1 clinical trial on fetoscopic repair of complex gastroschisis. Talk objectives: - Define the main cause of complex gastroschisis (GS). - Stratify patients with complex GS prenatally. - Describe the most important outcomes of postnatal management. - Summarize the safety and efficacy study in the fetal lamb model. - List the main inclusion criteria for phase 1 study at a fetal center. Register now to get the early bird registration discount: conference.aaplog.org

3

[D-3 Flow Chemistry Webinar] 📅 Join us next Monday 𝐀𝐩𝐫𝐢𝐥 𝟐𝟐𝐧𝐝 𝐚𝐭 𝟓𝐏𝐌 𝐂𝐄𝐓 / 𝟏𝟏𝐀𝐌 𝐄𝐓 for our SEQENS Pharmaceutical Solutions 𝐰𝐞𝐛𝐢𝐧𝐚𝐫!   ⏳It is still time to register! Connect with jean-baptiste Rouchet, Ph.D. and Jean-Yves LENOIR and 𝐥𝐞𝐚𝐫𝐧 𝐡𝐨𝐰 𝐭𝐨 𝐢𝐦𝐩𝐫𝐨𝐯𝐞 𝐭𝐡𝐞 𝐬𝐚𝐟𝐞𝐭𝐲 𝐚𝐧𝐝 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞𝐧𝐞𝐬𝐬 𝐨𝐟 𝐲𝐨𝐮𝐫 𝐩𝐫𝐨𝐜𝐞𝐬𝐬 𝐮𝐬𝐢𝐧𝐠 𝐅𝐥𝐨𝐰 𝐂𝐡𝐞𝐦𝐢𝐬𝐭𝐫𝐲.   𝐃𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐢𝐬 𝐰𝐞𝐛𝐢𝐧𝐚𝐫 𝐲𝐨𝐮 𝐰𝐢𝐥𝐥 𝐥𝐞𝐚𝐫𝐧: ✔️How to assess whether a Flow chemistry process should be studied as an alternative for your API synthesis, ✔️Insights on ICH Q13 guidance and how reproducibility and quality can be improved using continuous processes, ✔️Strategies to optimize a continuous process for an easier upscaling   𝐓𝐨 𝐫𝐞𝐠𝐢𝐬𝐭𝐞𝐫 ➡ https://lnkd.in/e2sUgA2X

38

1 commentaire

[#innaxe4eu] Zoom on insights from the Council of European BioRegions - CEBR! 🛠️ Last month, Council of European BioRegions - CEBR organized interviews and an interactive discussion on “Enhancing the impact of EU life sciences clusters actions through international cooperation” with stakeholders from the health and life science European sector to gather insights and recommendations on INNAXE’s future joint action plan.   📌 Cluster to cluster (C2C) cooperation is pivotal, grounded in mutual trust and involving cluster organizations, their companies, and stakeholders directly. 📌 EU clusters are motivated to collaborate in tackling shared challenges, demonstrating a collective commitment to innovation. 📌 Matching innovators with investors poses a significant challenge across diverse countries and ecosystems, emphasized as a top priority for many clusters. 📌 Real-world needs should inform the development of new products, with public procurement of innovation playing a role in enhancing healthcare quality and equity. 📌 European cooperation prioritizes advanced therapies and health data access, with regulatory and educational aspects taking precedence over technical considerations. Additionally, cascade funding is recognized as a valuable tool to support competitiveness, underscored by the importance of quality support provided by clusters. 🙏 Many thanks to Council of European BioRegions - CEBR BioRegions and the European ecosystem for their shared insights to consolidate our joint action plan. #innaxe4eu #Europe #innovation #health #clusters #lifescience #biotech #medtech Marta González Anaïs Le Corvec Alberto Baldi 

2

🧪 ASSAY | LIVE/DEAD staining ready in a few steps, directly inside the wells. With #Gri3D there is no need to move the samples 🔮 ! 👨‍🔬 #LIVE/DEAD assay is a standard for assessing the #toxicity of a treatment on cells. With #Gri3D, all steps can be performed on #organoids directly on the plate, from the incubation of the fluorescent probes to the imaging at a single-organoid level. The #fluorescently #labelled organoids can then be analyzed and the LIVE/DEAD ratios quantified in a high-throughput manner with a fully #automatable pipeline. You want to learn more about #Gri3D? Check our website: https://lnkd.in/eR2bXQJt and drop as a message to speak with our team of expert ([email protected]) 📩 #3Dcellculture #organoids #livedeadassay #workflows #assay #biotechnology #research #drugdiscovery #toxicity #automation

16